97 filings
Page 4 of 5
25
q56oz
15 Dec 22
Voluntary exchange delisting
4:19pm
8-A12B
ewk14869vzls3 s7
15 Dec 22
Registration of securities on exchange
4:16pm
8-K
7wfxbnqaqk 1zatu8uru
9 Dec 22
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
4:31pm
DEFA14A
q8qk9i9 k857tub
8 Dec 22
Additional proxy soliciting materials
8:31am
8-K
y25m1ypclynjb
5 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:39am
8-K
kwabx0idtw86841nlsb
29 Nov 22
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
4:30pm
DEF 14A
qb3gut6ve
25 Nov 22
Definitive proxy
6:16am
8-K
d8gs2hf h3
18 Nov 22
Departure of Directors or Certain Officers
4:31pm
8-K
n8o0y
9 Nov 22
Entry into a Material Definitive Agreement
4:50pm
424B5
sswm8
9 Nov 22
Prospectus supplement for primary offering
4:29pm
8-K
sndm7bwaohfjdb
8 Nov 22
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:19pm
10-Q
39i7barg1z497
8 Nov 22
Quarterly report
4:09pm
8-K
qi6zzhb
28 Oct 22
Termination of a Material Definitive Agreement
4:32pm
8-K
iknx2mmd8 8b
21 Oct 22
Entry into a Material Definitive Agreement
4:19pm
424B5
oprchm0c80xbev41bfal
21 Oct 22
Prospectus supplement for primary offering
4:16pm
8-K
gbn98g
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
8-K
daom4zrb2 53dho
13 Oct 22
Other Events
5:04pm
424B5
swm3xgk7m8k8v
13 Oct 22
Prospectus supplement for primary offering
4:56pm
S-8 POS
3uo8y4u l8c5sp1gprgp
13 Oct 22
Registration of securities for employees (post-effective amendment)
4:46pm
S-8 POS
8ewp9746crv
13 Oct 22
Registration of securities for employees (post-effective amendment)
4:44pm